MoonLake To Tap Into Komodo’s Technology and
Real-World Data To Unlock the Full Potential of Its Next-Gen
Nanobody® Therapy
MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a
clinical-stage biotechnology company focused on creating next-level
therapies for inflammatory diseases, and Komodo Health today
announce a new technology partnership to help improve treatment for
people living with inflammatory skin and joint diseases. The two
companies will collaborate to maximize the impact of MoonLake’s
nanobody-based therapy in hidradenitis suppurativa (HS) and active
psoriatic arthritis (PsA), two underdiagnosed diseases that have
significant unmet patient needs.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240410438883/en/
Through this multiyear technology partnership, MoonLake will
utilize Komodo’s Healthcare Map and platform technologies to enable
data-driven decision-making across its clinical operations,
medical, marketing, and market access teams. Komodo’s data and
technology applications will support MoonLake’s in-depth market
research, clinical trial site selection, go-to-market strategies,
and patient journey mapping — all aimed at accelerating the
development of new treatment options and improving outcomes for
patients with inflammatory skin and joint diseases.
Tino Anthamatten, VP, Marketing & Market Access &
Pricing, MoonLake Immunotherapeutics, commented: “We need an
experienced technology partner that can help accelerate our disease
insights for our clinical, medical, and commercial endeavors.
Komodo’s data-driven intelligence is expected to be a critical tool
as we work toward commercialization and delivering transformative
therapies to patients.”
Recent research underscores the challenges that Life Sciences
companies face in generating data-driven intelligence that can
support decision-making across the product life cycle. On average,
it takes seven months to identify and integrate data sources before
teams can even begin to generate insights.
Using Komodo’s software applications and Healthcare Map,
MoonLake was able to identify important findings, presented at its
R&D day last month, related to the HS market. The real-world
analysis of the U.S. patient population revealed that between 2016
and 2023, 2 million unique patients were diagnosed and treated for
HS, not including undiagnosed and untreated patients. The data also
revealed that, on average, 240,000 net new patients are diagnosed
and treated each year. This data helps substantiate the prevalence
of HS as ~2%, as stated in the literature. The real-world insights
from Komodo helped validate a future HS market size projected to
exceed $10B by 2035. Today there is a notably low penetration of
current biologics (around 3%) and a high dropout rate from these
interventions within the first year (median treatment duration of
11 months in a real-world setting). Furthermore, these insights
shed light on the challenges of care and that individuals living
with HS are being lost in their treatment journey. Over 50-60% of
patients take long-term antibiotics, and many are also prescribed
steroids and/or opioids. This real-world perspective substantiates
MoonLake’s market size estimates and highlights the need for more
effective therapies.
“We are thrilled to support MoonLake’s efforts to advance
scientific innovation and gain a deeper understanding of patient
journeys and unmet needs for people living with inflammatory
diseases,” said Web Sun, President and Co-Founder, Komodo Health.
“As MoonLake expects to commence phase 3 trials, we look forward to
helping their teams utilize data and analytics to evaluate the
market, develop their go-to-market and commercialization strategy,
and, most important, help quickly bring its Nanobody® therapy to
market, once approved, for patients who need it most.”
###
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage
biopharmaceutical company unlocking the potential of sonelokimab, a
novel investigational Nanobody® for the treatment of inflammatory
disease, to revolutionize outcomes for patients. Sonelokimab
inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F,
and IL-17F/F dimers that drive inflammation. The company’s focus is
on inflammatory diseases with a major unmet need, including
hidradenitis suppurativa and psoriatic arthritis – conditions
affecting millions of people worldwide with a large need for
improved treatment options. MoonLake was founded in 2021 and is
headquartered in Zug, Switzerland. Further information is available
at www.moonlaketx.com. The terms Nanobody® and Nanobodies® are
trademarks of Ablynx, a Sanofi company.
About Komodo Health
Komodo Health is a technology platform company creating the new
standard for real-world data and analytics by pairing the
industry’s most complete view of patient encounters with enterprise
software and machine learning that connects the dots between
individual patient journeys and large-scale health outcomes. Across
Life Sciences, payers, providers, and developers, Komodo helps its
customers unearth patient-centric insights at scale — marrying
clinical data with advanced algorithms and AI-powered software
solutions to inform decision-making, close gaps in care, address
disease burden, and help enterprises create a more cost-effective,
value-driven healthcare system. For more information, visit
Komodohealth.com.
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic and progressive
inflammatory arthritis associated with psoriasis primarily
affecting the peripheral joints. The clinical features of PsA are
diverse, involving pain, swelling, and stiffness of the joints,
which can result in restricted mobility and fatigue. PsA occurs in
up to 30% of patients with psoriasis, most commonly those aged
between 30 and 60 years. The symptom burden of PsA can have a
substantial negative impact on patient quality of life. Although
the exact mechanism of disease is not fully understood, evidence
suggests that activation of the IL-17 pathway plays an important
role in the disease pathophysiology.
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a severely debilitating chronic
skin condition resulting in irreversible tissue destruction. HS
manifests as painful inflammatory skin lesions, typically around
the armpits, groin, and buttocks. Over time, uncontrolled and
inadequately treated inflammation can result in irreversible tissue
destruction and scarring. The disease affects ~2% of the global
population, with three times more females affected than males.
Onset typically occurs in early adulthood, and HS has a profound
negative impact on quality of life, with a higher morbidity than
other dermatologic conditions. There is increasing scientific
evidence to support IL-17A- and IL-17F-mediated inflammation as a
key driver of the pathogenesis of HS, with other identified risk
factors including genetics, cigarette smoking, and obesity.
About Nanobodies®
Nanobodies® represent a new generation of antibody-derived
targeted therapies. They consist of one or more domains based on
the small antigen-binding variable regions of heavy-chain-only
antibodies (VHH). Nanobodies® have a number of potential advantages
over traditional antibodies, including their small size, enhanced
tissue penetration, resistance to temperature changes, ease of
manufacturing, and their ability to be designed into multivalent
therapeutic molecules with bespoke target combinations.
The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a
Sanofi company.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain “forward-looking statements”
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements include, but are not
limited to, statements regarding MoonLake’s expectations, hopes,
beliefs, intentions or strategies regarding the future including,
without limitation, statements regarding: plans for clinical trials
and research and development programs; including the initiation of
clinical programs in new indications; anticipated support from
regulatory agencies with respect to MoonLake’s development plans,
anticipated size and timing of enrollment for the VELA trial, the
sufficiency of data from the VELA trial to support regulatory
filings in the US and EU, the anticipated trial design for the VELA
trial and the timing of expected readouts; MoonLake’s expectations
regarding the potential market size for HS; the Company’s plans
with respect to the commencement of a Phase 3 trial in PsA; and the
efficacy of MoonLake’s products, if approved, including in relation
to other products. In addition, any statements that refer to
projections, forecasts, or other characterizations of future events
or circumstances, including any underlying assumptions, are
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions may identify
forward-looking statements, but the absence of these words does not
mean that statement is not forward looking.
Forward-looking statements are based on current expectations and
assumptions that, while considered reasonable by MoonLake and its
management, as the case may be, are inherently uncertain. New risks
and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. Actual results
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with MoonLake’s business in general and
limited operating history, difficulty enrolling patients in
clinical trials, and reliance on third parties to conduct and
support its clinical trials, and the other risks described in or
incorporated by reference into MoonLake’s Annual Report on Form
10-K for the year ended December 31, 2023 and subsequent filings
with the Securities and Exchange Commission.
Nothing in this press release should be regarded as a
representation by any person that the forward-looking statements
set forth herein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You
should not place undue reliance on forward-looking statements in
this press release, which speak only as of the date they are made
and are qualified in their entirety by reference to the cautionary
statements herein. MoonLake does not undertake or accept any duty
to release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or in the
events, conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240410438883/en/
Media: media@komodohealth.com MoonLake Immunotherapeutics
Media Patricia Marques de Sousa media@moonlaketx.com ICR Consilium
Mary-Jane Elliott, Namrata Taak, Ashley Tapp Tel.: +44 (0) 20 3709
5700 moonlake@consilium-cooms.com
MoonLake Immunotherapeut... (NASDAQ:MLTX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
MoonLake Immunotherapeut... (NASDAQ:MLTX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
